



## Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

September 1, 2022

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn<sup>®</sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in upcoming investor conferences in September. With an initial focus in oncology, Foghorn's Gene Traffic Control<sup>®</sup> Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

### **Morgan Stanley 20<sup>th</sup> Annual Global Healthcare Conference**

Monday, September 12, 2022, at 8:45 a.m. ET

Please find a link to the fireside chat [here](#)

### **H.C. Wainwright 24<sup>th</sup> Annual Global Investment Conference**

Tuesday, September 13, 2022, at 10:00 a.m. ET

Please find a link to the presentation [here](#)

A webcast of the fireside chat and presentation will be accessible under "Events & Presentations" in the Investors section of the Company's website, [www.foghornrx.com](http://www.foghornrx.com), and will remain available for up to 90 days.

### **About Foghorn Therapeutics**

Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies. Visit our website at [www.foghornrx.com](http://www.foghornrx.com) for more information on the company, and follow us on [Twitter](#) and [LinkedIn](#).

### **Contact:**

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)

[bstrain@foghornrx.com](mailto:bstrain@foghornrx.com)

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)

[khellsvik@foghornrx.com](mailto:khellsvik@foghornrx.com)

Michael Lampe, ScientPR (Media)

[michael@scientpr.com](mailto:michael@scientpr.com)

Hans Vitzthum, LifeSci Advisors (Investors)

[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)